Key Takeaways
- Independent commercialization can preserve economics and build enterprise capability; partnership can reduce capital and execution risk.
- Start with the market—prescriber universe, concentration, access burden and competitive intensity shape feasibility.
- Capital is not the only constraint; organizational capability and leadership bandwidth matter.
- Do the commercial work before committing—build the model, then evaluate alternatives.
For an emerging biotechnology company approaching late-stage development, few strategic decisions carry greater implications than whether to commercialize independently.
Going alone can preserve economics and build long-term enterprise capability. Partnering can reduce capital requirements and execution risk.
Neither strategy is universally correct. The decision should begin with a realistic understanding of what commercialization actually requires.
Executive opinion paper
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.
